Tesaro shares soared 39 percent Friday upon a Bloomberg report that the pharmaceutical company will explore the opportunity of a sale.
This comes exactly one week after the cancer drug company fell more than 20 percent during after-hours trading after the release of drug trial results for treatment of small cell lung cancer. A spokesperson declined to comment.
Tesaro also explored a sale in May 2017, but it did not come to a close. Shares then fell more than 11 percent during that time.
